FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1082-1083 October 19, 1995 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Andrade, S. E.

To the Editor: In their article on the discontinuation of antihyperlipidemic drugs, Andrade et al. (April 27 issue)¹ discuss the generalizability of the results of randomized trials. Specifically, they state that discontinuation rates in randomized trials may not accurately reflect the tolerability or effectiveness of therapy in the general population. In reaching their conclusions, however, they appear to overlook an additional factor. There were 2369 study patients and 3223 courses of therapy. During the study period 854 participants therefore changed therapy.

The period of the study corresponds to the clinical introduction of lovastatin and simvastatin. The early results of trials . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.